Maxime Verhoeven

49 An indirect comparison of treat-to-target strategies in early RA Table 2 (continued) Outcomes based on adjusted analyses using pooled outcomes of 40 imputed datasets. TCZ+MTX= tocilizumab + methotrexate strategy arm; MTX+Pred= methotrexate + prednisone strategy arm, TCZ= tocilizumab + placebo strategy arm; DAS28= disease activity score assessing 28 joints; CI= confidence interval; RR= relative risk; m-CDAI= modified clinical disease activity index; ConRew= continuity rewarded based on DAS28 remission; HAQ= health assessment questionnaire; SvdH= Sharp van der Heijde; IRR= incidence rate ratio; ALT= alanine aminotransferase; AST= aspartate aminotransferase; AE= adverse event. Figure 1a Mean (SE) DAS28 over time for each strategy arm as predicted by model. Figure 1b Mean (SE) modified CDAI in each strategy arm as predicted by model, based on back transformation to original scale. DAS28= disease activity score assessing 28 joints; M-CDAI= modified CDAI; SE= standard error; MTX (ref)= methotrexate + placebo strategy used as reference arm in the analysis; MTX+Pred= methotrexate + prednisone strategy arm; TCZ+MTX= tocilizumab + methotrexate strategy arm; TCZ= tocilizumab + placebo strategy arm. 3